微小RNA在乳腺癌干细胞中的作用

doi:10.3760/cma.j.issn.1673-422X.2014.12.002

摘要/Abstract

摘要： 肿瘤干细胞是一类具有自我更新以及多向分化潜能的特殊肿瘤细胞群，在肿瘤形成、转移、抗癌治疗和癌症复发中发挥着显著作用。大量研究发现，微小RNA参与了调节乳腺癌干细胞的维持、生长以及习性，为乳腺癌的诊断、预后和治疗开辟了新的途径。

关键词: 微RNAs, 肿瘤干细胞, 乳腺肿瘤

Abstract: The role of microRNAs in breast cancer stem cellsMao Changfei, Wu Jianzhong, Tang Jinhai. Corresponding author:【Abstract】Cancer stem cells are a kind of cancer cell group with the ability of selfrenewal and various diferentiation potentials. Recent studies have implicated that they play a significant role in tumor formation, metastasis, resistance to anticancer therapies and cancer recurrence. Many studies show that microRNAs are involved in the maintenance, growth and behavior of breast cancer stem cells(BCSCs), paving a new way for diagnosis, prognosis and therapy of breast cancer.

Key words: MicroRNAs, Neoplastic stem cells, Breast neoplasms

茅昌飞, 吴建中, 唐金海. 微小RNA在乳腺癌干细胞中的作用[J]. 国际肿瘤学杂志, 2014, 41(12): 884-887.

MAO Chang-Fei, WU Jian-Zhong, TANG Jin-Hai. The role of microRNAs in breast cancer stem cells[J]. Journal of International Oncology, 2014, 41(12): 884-887.

参考文献

［1］ Wicha MS, Liu S, Dontu G. Cancer stem cells: an old ideaa paradigm shift［J］. Cancer Res, 2006, 66(4): 18831890. ［2］ NanaSinkam SP, Croce CM. Clinical applications for micrornas in cancer［J］. Clin Pharmacol Ther, 2013, 93(1): 98104. ［3］ Sempere LF, Christensen M, Silahtaroglu A, et al. Altered microrna expression confined to specific epithelial cell subpopulations in breast cancer［J］. Cancer Res, 2007, 67(24): 1161211620. ［4］ Yu F, Yao H, Zhu P, et al. Let7 regulates self renewal and tumorigenicity of breast cancer cells［J］. Cell, 2007, 131(6): 11091123. ［5］ Johnson CD, EsquelaKerscher A, Stefani G, et al. The let7 microrna represses cell proliferation pathways in human cells［J］. Cancer Res, 2007, 67(16): 77137722. ［6］ Wang Y, Hu X, Greshock J, et al. Genomic DNA copynumber alterations of the let7 family in human cancers［J］. PLoS One, 2012, 7(9): e44399. ［7］ Ambros V. Micrornas: Tiny regulators with great potential［J］. Cell, 2001, 107(7): 823826. ［8］ Yu F, Deng H, Yao H, et al. Mir30 reduction maintains selfrenewal and inhibits apoptosis in breast tumorinitiating cells［J］. Oncogene, 2010, 29(29): 41944204. ［9］ Shimono Y, Zabala M, Cho RW, et al. Downregulation of mirna200c links breast cancer stem cells with normal stem cells［J］. Cell, 2009, 138(3): 592603. ［10］ Iliopoulos D, LindahlAllen M, Polytarchou C, et al. Loss of mir200 inhibition of suz12 leads to polycombmediated repression required for the formation and maintenance of cancer stem cells［J］. Mol cell, 2010, 39(5): 761772. ［11］ Okuda H, Xing F, Pandey PR, et al. miR7 suppresses brain metastasis of breast cancer stemlike cells by modulating klf4［J］. Cancer Res, 2013, 73(4): 14341444. ［12］ Zhu Y, Yu F, Jiao Y, et al. Reduced miR128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi1 and ABCC5［J］. Clin Cancer Res, 2011, 17(22): 71057115. ［13］ Qian P, Banerjee A, Wu ZS, et al. Loss of snail regulated mir1282 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells［J］. Cancer Res, 2012, 72(22): 60366050. ［14］ Yu F, Jiao Y, Zhu Y, et al. Microrna 34c gene downregulation via DNA methylation promotes selfrenewal and epithelialmesenchymal transition in breast tumorinitiating cells［J］. J Biol Chem, 2012, 287(1): 465473. ［15］ Zhang X, Wan G, Mlotshwa S, et al. Oncogenic wip1 phosphatase is inhibited by mir16 in the DNA damage signaling pathway［J］. Cancer Res, 2010, 70(18): 71767186. ［16］ HwangVerslues WW, Chang PH, Wei PC, et al. Mir495 is upregulated by e12/e47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of ecadherin and redd1［J］. Oncogene, 2011, 30(21): 24632474. ［17］ Zhang Y, Eades G, Yao Y, et al. Estrogen receptor alpha signaling regulates breast tumorinitiating cells by downregulating mir140 which targets the transcription factor SOX2［J］. J Biol Chem, 2012, 287(49): 4151441522. ［18］ Li Q, Yao Y, Eades G, et al. Downregulation of mir140 promotes cancer stem cell formation in basallike early stage breast cancer［J］. Oncogene, 2014, 33(20): 25892600.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[5]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[6]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[7]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[10]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[11]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[12]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[13]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[14]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[15]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.